N-Amino-nortropan | 1003-94-7

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: N-Amino-nortropan
• 英文别名: 8-Azabicyclo[3.2.1]octan-8-amine；8-azabicyclo[3.2.1]octan-8-amine
• CAS: 1003-94-7
• 化学式: C₇H₁₄N₂
• 分子量: 126.202
• InChiKey: HXQNDYLLAQMCRX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• ORGANIC ELECTROLUMINESCENT ELEMENT, AND ILLUMINATION DEVICE AND DISPLAY DEVICE EACH COMPRISING THE ELEMENT
  申请人：Konica Minolta Holdings, Inc.

  公开号：EP3046156A1

  公开（公告）日：2016-07-20

  Disclosed is an organic electroluminescent element which has high luminous efficiency, a low driving voltage, excellent heat resistance, excellent raw stock storability and a long service life.

  本发明公开了一种有机电致发光元件，它具有高发光效率、低驱动电压、优异的耐热性、出色的原材料储存性和较长的使用寿命。
• DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP3560499A1

  公开（公告）日：2019-10-30

  The present invention relates to the use of a compound of general Formula (1), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of diseases characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators.

  本发明涉及通式（1）化合物的用途、 可选择以其同系物、外消旋体、对映体、非对映异构体及其混合物的形式，以及可选择以其药理学上可接受的酸加成盐、溶液剂、水合物、多晶型物、生理功能衍生物或原药的形式，用于制备药物组合物，通过抑制作为有丝分裂调节因子的polo样激酶，治疗以人或非人哺乳动物体内细胞异常增殖为特征的疾病。
• PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE
  申请人：Taisho Pharmaceutical Co., Ltd.

  公开号：EP3666766A1

  公开（公告）日：2020-06-17

  The present invention provides a compound represented by formula [I] shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme. (in formula [I] above, the structure represented by formula [II] below: represents any of the structures represented by formula group [III] below: R1, R2, R3, and R4 independently represent a hydrogen atom, a fluorine atom, methyl, or the like, R5 represents any of the structures represented by formula group [IV]:

  本发明提供了一种由下式[I]代表的化合物或其药学上可接受的盐，对 20-HETE 生成酶具有抑制作用。 (上式[I]中，下式[II]所代表的结构： 代表下式组[III]所代表的任何一种结构： R1、R2、R3 和 R4 独立地代表氢原子、氟原子、甲基或类似物、 R5 代表式组 [IV] 所代表的任何一种结构：
• JANUS KINASE (JAK) FAMILY INHIBITOR, PREPARATION OF SAME, AND APPLICATIONS THEREOF
  申请人：Jiangsu Vcare Pharmatech Co., Ltd

  公开号：EP3919494A1

  公开（公告）日：2021-12-08

  A 7-azaindole derivative having the structure of formula (I), a pharmaceutical composition containing the compound of formula (I), and uses of the compound in preparing a medicament for preventing or treating Janus kinase (JAK) family-related diseases, specifically, uses in preventing or treating inflammatory diseases related to protein tyrosine kinase.

  一种具有式（I）结构的 7-氮杂吲哚衍生物，一种含有式（I）化合物的药物组合物，以及该化合物在制备预防或治疗 Janus 激酶（JAK）家族相关疾病的药物中的用途，特别是在预防或治疗与蛋白酪氨酸激酶相关的炎症性疾病中的用途。
• [EN] JANUS KINASE (JAK) FAMILY INHIBITOR, PREPARATION OF SAME, AND APPLICATIONS THEREOF<br/>[FR] INHIBITEUR DE LA FAMILLE DES JANUS KINASES (JAK), SA PRÉPARATION ET SES APPLICATIONS<br/>[ZH] 两面神激酶JAK家族抑制剂及其制备和应用
  申请人：JIANGSU VCARE PHARMATECH CO LTD

  公开号：WO2020156271A1

  公开（公告）日：2020-08-06

  一种具有式(I)结构的7-氮杂吲哚衍生物、含有式(I)化合物的药物组合物及所述化合物在制备预防或治疗两面神激酶JAK家族相关疾病药物的用途，特别是用于预防或治疗与蛋白质酪氨酸激酶相关的炎症疾病的用途。